Three sector advisors told Dealreporter that they believe Biogen (BIIB) could restock its development pipeline with late-stage acquisitions in the neuroscience and gene therapy areas. One advisor said that Sage Therapeutics (SAGE) “could be a good fit if Biogen wanted to make a big splash, but said that such large-scale M&A seems unlikely for the company,” Dealreporter said, according to contacts. Sage Therapeutics shares saw a brief spike coincidental with the report from Dealreporter. In late morning trading, Sage shares are up 34c, or 0.2%, to $162.13.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.